InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $14.500 0.16 (1.09%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$4,927 Change in substantial holding 24 Jul 2026 8:21AM $15.170 $14.500 fallen by 4.42%
$4,927 Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress 21 Jul 2026 8:26AM $15.100 $14.500 fallen by 3.97%
$4,927 Notification of cessation of securities - TLX 10 Jul 2026 8:24AM $16.940 $14.500 fallen by 14.40%
$4,927 Notification regarding unquoted securities - TLX 10 Jul 2026 8:24AM $16.940 $14.500 fallen by 14.40%
$4,927 Application for quotation of securities - TLX 10 Jul 2026 8:24AM $16.940 $14.500 fallen by 14.40%
$4,927 Change in substantial holding 8 Jul 2026 5:49PM $16.580 $14.500 fallen by 12.55%
$4,927 Ceasing to be a substantial holder 3 Jul 2026 1:36PM $16.710 $14.500 fallen by 13.23%
$4,927 FDA Alignment to Advance ProstACT Global Phase 3 Trial 2 Jul 2026 10:07AM $17.060 $14.500 fallen by 15.01%
$4,927 Change in substantial holding 1 Jul 2026 12:38PM $17.225 $14.500 fallen by 15.82%
$4,927 Change in substantial holding 1 Jul 2026 8:17AM $16.580 $14.500 fallen by 12.55%
$4,927 Becoming a substantial holder 30 Jun 2026 5:24PM $16.580 $14.500 fallen by 12.55%
$4,927 Becoming a substantial holder 25 Jun 2026 8:16AM $15.730 $14.500 fallen by 7.82%
$4,927 Ceasing to be a substantial holder 23 Jun 2026 5:32PM $14.560 $14.500 fallen by 0.41%
$4,927 Appendix 3Y Change in Director Interest D Gill 17 Jun 2026 8:24AM $13.850 $14.500 risen by 4.69%
$4,927 Change in substantial holding 9 Jun 2026 8:13AM $13.310 $14.500 risen by 8.94%
$4,927 Notification regarding unquoted securities - TLX 1 Jun 2026 3:26PM $13.035 $14.500 risen by 11.24%
$4,927 Appendix 3Y Change in Director Interest - C Behrenbruch 1 Jun 2026 3:20PM $13.035 $14.500 risen by 11.24%
$4,927 Appendix 3Y Change in Director Interest - M McDonald 1 Jun 2026 3:16PM $13.010 $14.500 risen by 11.45%
$4,927 Appendix 3Y Change in Director Interest - W Jellison 1 Jun 2026 3:15PM $13.010 $14.500 risen by 11.45%
$4,927 Appendix 3Y Change in Director Interest - Maria Rivas 1 Jun 2026 3:12PM $13.010 $14.500 risen by 11.45%
$4,927 Appendix 3Y Change in Director Interest - David Gill 1 Jun 2026 3:11PM $13.010 $14.500 risen by 11.45%
$4,927 Becoming a substantial holder 26 May 2026 4:50PM $13.230 $14.500 risen by 9.60%
$4,927 Results of Annual General Meeting 21 May 2026 1:00PM $14.280 $14.500 risen by 1.54%
$4,927 Telix Annual General Meeting Presentation 21 May 2026 9:39AM $14.000 $14.500 risen by 3.57%
$4,927 Telix Annual General Meeting Chairman and CEO Addresses 21 May 2026 9:38AM $14.000 $14.500 risen by 3.57%

1 - 25 of 947 results

Page 1 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.